Gilead Sciences Q1 2026 Revenue Beats Estimates at $6.96B
Gilead Sciences (NASDAQ:GILD) reported Q1 2026 results that beat revenue expectations. Revenue came in at $6.96 billion, up 4.4% year over year, while non-GAAP earnings per share of $2.03 exceeded consensus by 6.3%.
Key Numbers
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 2026 results that surpassed market revenue expectations. Revenue reached $6.96 billion, a 4.4% increase year over year, and non-GAAP earnings per share of $2.03 beat analyst estimates by 6.3%.
Key Financial Results
| Metric | Q1 2026 | vs. Estimates |
|---|---|---|
| Revenue | $6.96B | Beat |
| Non-GAAP EPS | $2.03 | Beat by 6.3% |
| Revenue Growth (YoY) | 4.4% | — |
Key Highlights
Gilead attributed the strong performance to growth in its core HIV and antiviral product portfolio. No further details on specific growth drivers were provided.
Guidance
The company expects full-year 2026 revenue of approximately $30.2 billion, close to analyst estimates.
Stock Impact
The stock reaction was not explicitly mentioned, but beating expectations is generally viewed positively.
What This Means for Investors
Gilead's Q1 performance demonstrates resilience with revenue growth and earnings above expectations. The guidance aligns with estimates, suggesting stable performance ahead. Investors should monitor pipeline developments and competitive dynamics in the biopharmaceutical sector.
Frequently Asked Questions
Found this useful? Share it